Oncternal Therapeutics Inc. [NASDAQ: ONCT] stock went on an upward path that rose over 15.48% on Wednesday, amounting to a one-week price increase of more than 6.07%. The company report on April 13, 2021 that Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company with extensive experience providing strategic, transactional, financial, and operational advice to life sciences companies.
“Chase is a highly seasoned and pragmatic General Counsel and business leader with a broad background spanning both biotech and technology companies that will help to position Oncternal for our next stage of growth,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
Over the last 12 months, ONCT stock rose by 163.49%. The average equity rating for ONCT stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $310.09 million, with 49.36 million shares outstanding and 43.50 million shares in the current float. Compared to the average trading volume of 1.65M shares, ONCT stock reached a trading volume of 1906273 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Oncternal Therapeutics Inc. [ONCT]:
Oppenheimer have made an estimate for Oncternal Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 07, 2021. While these analysts kept the previous recommendation, Northland Capital raised their target price to Outperform. The new note on the price target was released on February 23, 2021, representing the official price target for Oncternal Therapeutics Inc. stock.
The Average True Range (ATR) for Oncternal Therapeutics Inc. is set at 0.86, with the Price to Sales ratio for ONCT stock in the period of the last 12 months amounting to 91.20. The Price to Book ratio for the last quarter was 1.73.
ONCT Stock Performance Analysis:
Oncternal Therapeutics Inc. [ONCT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.07. With this latest performance, ONCT shares dropped by -26.55% in over the last four-week period, additionally plugging by 292.90% over the last 6 months – not to mention a rise of 163.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONCT stock in for the last two-week period is set at 45.30, with the RSI for the last a single of trading hit 44.47, and the three-weeks RSI is set at 46.95 for Oncternal Therapeutics Inc. [ONCT]. The present Moving Average for the last 50 days of trading for this stock 7.32, while it was recorded at 6.23 for the last single week of trading, and 4.29 for the last 200 days.
Insight into Oncternal Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Oncternal Therapeutics Inc. [ONCT] shares currently have an operating margin of -519.76. Oncternal Therapeutics Inc.’s Net Margin is presently recorded at -510.37.
Return on Total Capital for ONCT is now -27.52, given the latest momentum, and Return on Invested Capital for the company is -27.05. Return on Equity for this stock declined to -27.07, with Return on Assets sitting at -24.51. When it comes to the capital structure of this company, Oncternal Therapeutics Inc. [ONCT] has a Total Debt to Total Equity ratio set at 0.04. Additionally, ONCT Total Debt to Total Capital is recorded at 0.04, with Total Debt to Total Assets ending up at 0.03.
Reflecting on the efficiency of the workforce at the company, Oncternal Therapeutics Inc. [ONCT] managed to generate an average of -$1,230,357 per employee.Oncternal Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 20.10 and a Current Ratio set at 20.10.
ONCT Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ONCT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Oncternal Therapeutics Inc. go to 0.00%.
Oncternal Therapeutics Inc. [ONCT] Insider Position Details
There are presently around $48 million, or 21.60% of ONCT stock, in the hands of institutional investors. The top three institutional holders of ONCT stocks are: VANGUARD GROUP INC with ownership of 1,681,504, which is approximately 504.193% of the company’s market cap and around 14.80% of the total institutional ownership; IKARIAN CAPITAL, LLC, holding 1,030,323 shares of the stock with an approximate value of $5.92 million in ONCT stocks shares; and 683 CAPITAL MANAGEMENT, LLC, currently with $4.19 million in ONCT stock with ownership of nearly New of the company’s market capitalization.
Positions in Oncternal Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 43 institutional holders increased their position in Oncternal Therapeutics Inc. [NASDAQ:ONCT] by around 7,363,019 shares. Additionally, 9 investors decreased positions by around 3,154,514 shares, while 9 investors held positions by with 2,097,487 shares. The mentioned changes placed institutional holdings at 8,420,046 shares, according to the latest SEC report filing. ONCT stock had 35 new institutional investments in for a total of 5,182,956 shares, while 6 institutional investors sold positions of 2,728,366 shares during the same period.